-+ 0.00%
-+ 0.00%
-+ 0.00%

New Data for Precision Biologics, Inc. PB-223 ADC against novel tumor-specific target on human cancers revealed at SITC 2026

Barchart·11/06/2026 08:18:00
Listen to the news

BETHESDA, Md., Nov. 6, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD announces presentation of new data describing in-vivo efficacy of its novel tumor-specific antibody-drug-conjugate PB-223 ADC. Recent tumor killing data showing specific non-toxic anti-tumor activity in human cancer expressing truncated core 2 O-glycans will be reported in "In vivo efficacy of the antibody-drug conjugate (ADC) PB-vcMMAE-5 in an ovarian cancer patient-derived xenograft (PDX) model expressing truncated core 2 O-glycans", at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2026, November 7th, 2026, Phoenix Convention Center, Phoenix, AZ.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.